Adverum Biotechnologies, Inc.
ADVM
$2.93
-$0.05-1.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -60.53M | -27.13M | -18.48M | -24.79M | -28.67M |
| Total Depreciation and Amortization | 810.00K | 890.00K | 956.00K | 997.00K | 1.01M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.54M | 3.01M | 4.04M | 4.32M | 10.20M |
| Change in Net Operating Assets | 8.93M | 2.11M | -6.36M | -3.78M | -3.87M |
| Cash from Operations | -28.25M | -21.12M | -19.84M | -23.25M | -21.33M |
| Capital Expenditure | -61.00K | -221.00K | -16.00K | -90.00K | -192.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4.13M | -13.13M | -2.31M | -21.94M | -9.69M |
| Cash from Investing | -4.19M | -13.35M | -2.33M | -22.03M | -9.88M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 239.00K | 0.00 | -- | 119.88M | 242.00K |
| Repurchase of Common Stock | -- | -- | -116.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -76.00K |
| Cash from Financing | 239.00K | 0.00 | -116.00K | 119.88M | 166.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -32.20M | -34.47M | -22.29M | 74.61M | -31.04M |